Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 2Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 14OTHER 9NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 30Carboplatin 14Biopsy 14Radiation 13Cyclophosphamide 13Radiotherapy 11daratumumab 10Vincristine 10Dexamethasone 10Surgical Procedures, Operative 9Etoposide 9Lenalidomide 8X-Rays 7Observation 7Leucovorin 7Irinotecan 7Doxorubicin 7Cisplatin 7durvalumab 6dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Watchful Waiting 6Radiosurgery 6Docetaxel 6Calcium Dobesilate 6pembrolizumab 5Stem Cell Transplantation 5Standard of Care 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NETWORK × Prednisolone × Clear all
NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡